Related Experiment Video

Updated: Oct 10, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

911

Cardiac injury and COVID-19 associated coagulopathy in patients with acute SARS-CoV-2 pneumonia: A rotational

Federico Capone1, Alberto Cipriani2, Leonardo Molinari1

  • 1Division of Internal Medicine, Department of Medicine, Padua University Hospital, Padua, Italy.

Advances in Medical Sciences
|December 15, 2021
PubMed

Insights

COVID-19 cardiac injury is not linked to abnormal blood clotting. Researchers found no differences in coagulation tests between patients with and without heart damage, suggesting other factors cause cardiac issues in COVID-19 patients.

Area of Science:

  • Cardiology
  • Hematology
  • Infectious Diseases

Background:

  • Coronavirus disease 2019 (COVID-19) is a systemic inflammatory condition.
  • Coagulopathy and thromboembolic complications are observed in COVID-19.
  • Cardiac injury is a frequent complication in hospitalized COVID-19 patients.

Purpose of the Study:

  • To investigate the association between abnormal coagulation and cardiac injury in COVID-19 patients.
  • To compare coagulation parameters in COVID-19 patients with and without cardiac injury.

Main Methods:

  • Retrospective cross-sectional study of 104 hospitalized COVID-19 patients.
  • Comparison of traditional coagulation tests and rotational thromboelastometry (ROTEM).
  • Cardiac injury defined by elevated high-sensitivity cardiac troponin I (hs-cTnI).

Main Results:

  • No significant differences in traditional coagulation parameters between groups.
  • Rotational thromboelastometry showed abnormal maximum clot firmness (MCF) in 77% of patients, but no difference between groups.
  • Cardiac injury, not hypercoagulability, was associated with mortality.

Conclusions:

  • Hospitalized COVID-19 patients with and without cardiac injury show no differences in coagulation parameters.
  • Mechanisms other than hypercoagulability may cause cardiac injury in COVID-19.
  • Further research is needed to elucidate the pathophysiology of cardiac injury in COVID-19.
Abstract

Keywords:
COVID-19Coronary thrombosisHypercoagulabilityRotational thromboelastometryTroponin

More Related Videos

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.0K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
67
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
390
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
76
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
40
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
108
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
173